‘Japanese walking': Does the TikTok trend live up to the hype?
TikTok users are rallying behind another trend – one that is not particularly new, but yields fat-loss and fitness results without requiring any fancy gear.
The long-practiced method, dubbed 'Japanese Walking,' also known to many as interval walking training has been garnering attention on social media for its well-known effects on endurance, cardiovascular health and fat loss – all in under 30 minutes a day.
Interval walking is a simple technique that consists of a 3-by-3 cycle. Instead of walking at a consistent pace for 30 minutes, this cycle involves walking briskly for three minutes, followed by slow walking for another three minutes and repeating this method for 30 minutes.
Interval walking is also effective in reducing factors associated with lifestyle and metabolic diseases. It improves glycemic control for people with Type 2 diabetes and can help people with chronic diseases or obesity, according to an article published in the journal Applied Physiology, Nutrition, and Metabolism from Canadian Science Publishing.
This method was originally developed for the elderly in Japan in 2009, so they could exercise with minimal requirements, equipment and supervision and still be able to physically support themselves, according to the journal.
'Interval walking training is a feasible and effective training regimen for older, fragile individuals. It significantly enhances fitness, muscle strength and health markers,' the publication reads.
Brent Bishop, a fitness expert and co-founder of First Place Fuel, a nutrition supplement company based in Toronto, calls it an 'effective' method.
'(For) somebody who is in their 60s, and those who are just starting out (and) are a little bit less fit,' Bishop explained in an interview with CTVNews.ca. 'They can get their heart rate up decently by walking at a brisk pace.'
According to him, this exercise could end up increasing the heart rate up to nearly 80 per cent, which supports cardiovascular health.
'It is one of the most underrated forms of exercise,' he said. 'A lot of people don't do enough of it. There's a lot of sitting, (and) less walking and moving.'
Even moderate amounts of exercise can increase blood flow to the brain, which in turn decreases the risk of dementia and increases cognitive performance and memory function, Bishop said.
'Walking can be done every single day, and it can be done quite safely without putting a lot of undue stress on the joints.'
Bishop points out that the trend is not saying anything experts weren't already aware of. However, he says, the trend is real and has many health benefits, especially for middle- and older-aged people, or anyone with chronic illnesses or injuries.
Meanwhile, he stresses the importance of strength and weight training alongside cardiovascular exercises to reach the optimal level of fitness and weight management.
'Results are about consistency,' Bishop said. 'It's consistency over intensity and duration.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Diabetes Clinical Trial Pipeline Experiences Rapid Expansion as Over 200+ Leading Companies Advance Novel Therapies
DelveInsight's, ' Diabetes Pipeline Insight 2025 ' report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight's comprehensive report today! @ Diabetes Pipeline Outlook Key Takeaways from the Diabetes Pipeline Report In June 2025, Eli Lilly and Company announced a study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India. The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks). DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment. The leading Diabetes Companies such as vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others. Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others. Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs Diabetes Emerging Drugs Profile Cadisegliatin: vTv Therapeutics Cadisegliatin, also known as TTP399, is an innovative oral medication developed by vTv Therapeutics, designed as a liver-selective glucokinase activator. It aims to serve as an adjunctive therapy to insulin for individuals with type 1 diabetes (T1D). This drug has been recognized for its potential to improve glycemic control by enhancing hepatic glucose uptake and glycogen storage independently of insulin, addressing a critical need in diabetes management. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diabetes. LY-3209590: Eli Lilly and Company Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes. CT-388: Roche CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). CT-388 was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no ß-arrestin recruitment on either receptor. This biased signaling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Type 2 Diabetes Mellitus. HU6: Rivus Pharmaceuticals HU6 is an investigational, first-in-class oral therapy developed by Rivus Pharmaceuticals. It belongs to a new drug class called Controlled Metabolic Accelerators (CMAs), which are designed to selectively increase fat metabolism, leading to fat loss while preserving muscle mass. HU6 works by subtly increasing resting metabolism, specifically by activating a process called mitochondrial uncoupling. This process increases the oxidation of sugars and fats without reducing ATP (energy) production, resulting in the selective reduction of accumulated fat throughout the body. Currently, the drug is in the Phase II stage of development to treat Diabetes. XW014: Sciwind Biosciences XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes. K-833: Kallyope Inc. K-833 is an investigational oral small-molecule developed by Kallyope Inc., designed as a nutrient receptor agonist for the treatment of obesity and type 2 diabetes. K-833, often studied in combination with Kallyope's other candidate K-757, targets G-protein coupled receptors (specifically GPR119), which are involved in the release of hormones that suppress appetite and regulate glucose. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes. The Diabetes Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment. Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight's detailed report now! @ New Diabetes Drugs Diabetes Companies vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others. The Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diabetes Products have been categorized under various Molecule types such as, Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Diabetes Market Drivers and Barriers Scope of the Diabetes Pipeline Report Coverage- Global Diabetes Companies- vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. and others. Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others. Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Diabetes: Overview Pipeline Therapeutics Therapeutic Assessment Diabetes– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Cadisegliatin: vTv Therapeutics Drug profiles in the detailed report….. Mid-Stage Products (Phase II) CPL207280: Celon Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) KN056: Suzhou Alphamab Co., Ltd. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diabetes Key Companies Diabetes Key Products Diabetes- Unmet Needs Diabetes- Market Drivers and Barriers Diabetes- Future Perspectives and Conclusion Diabetes Analyst Views Diabetes Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Globe and Mail
2 days ago
- Globe and Mail
Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern's RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern's strategic partnership potential. To view the full press release, visit About Lantern Pharma Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers. On average, Lantern's newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $2.5 million per program. NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company's newsroom at About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
Globe and Mail
2 days ago
- Globe and Mail
KISQALI Achieves Significant Market Growth, Strengthening Its Position in Breast Cancer and CDK4/6 Inhibitors Segment
KISQALI is a promising CDK4/6 inhibitor used in combination with aromatase inhibitors for the treatment of HR-positive, HER2-negative breast cancer. Its market potential remains strong, driven by its efficacy in prolonging progression-free survival in early and metastatic stages of the disease. With a growing demand for targeted therapies and increasing patient awareness, KISQALI's market is expected to expand further. DelveInsight's ' KISQALI Market Size, Forecast, and Market Insight Report ' highlights the details around KISQALI, a cyclin-dependent kinase (CDK4/6 inhibitor). The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of KISQALI. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Novartis' KISQALI (ribociclib) Overview KISQALI (ribociclib) is a targeted cyclin-dependent kinase inhibitor, a type of drug that helps slow cancer progression by blocking two proteins, cyclin-dependent kinase 4 and 6 (CDK4/6). When these proteins are overactive, they can cause cancer cells to grow and divide too quickly. By specifically targeting CDK4/6, KISQALI aims to prevent cancer cells from replicating uncontrollably. KISQALI was developed by Novartis in collaboration with Astex Pharmaceuticals. In addition to its FDA approval for early breast cancer (EBC) patients in the US, KISQALI is undergoing regulatory reviews in other regions, including the EU and China. KISQALI has received approval for treating metastatic breast cancer (MBC) in 99 countries, including the US and EU. In the US, it is approved for adults with HR+/HER2- advanced or MBC in combination with an aromatase inhibitor (AI) as initial endocrine therapy (ET) or fulvestrant as initial ET or after disease progression. In the EU, it is approved for women with HR+/HER2- advanced or MBC in combination with an AI or fulvestrant as initial ET or after disease progression. In pre- or peri-menopausal women, the ET should be combined with a luteinizing hormone-releasing hormone agonist. In the context of MBC, KISQALI has consistently shown significant overall survival benefits in three Phase III trials. The NCCN Guidelines for breast cancer recommend KISQALI (ribociclib) as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment in HR+/HER2- patients when combined with an AI, making KISQALI the preferred first-line treatment in the US for this patient group. Additionally, KISQALI received the highest score among CDK4/6 inhibitors on the ESMO Magnitude of Clinical Benefit Scale, scoring five out of five for first-line treatment of pre-menopausal patients with HR+/HER2- advanced breast cancer. KISQALI, when combined with either letrozole or fulvestrant, earned a four out of five rating for post-menopausal patients with HR+/HER2- advanced breast cancer in the first-line setting. KISQALI Dosage and Administration The suggested KISQALI dosage is 600 mg (equivalent to three 200 mg film-coated tablets) taken orally once a day for 21 consecutive days, followed by a 7-day break from treatment, making a full cycle of 28 days. KISQALI can be taken with or without food. When used in combination with KISQALI, the recommended dose of fulvestrant is 500 mg, administered on Days 1, 15, 29, and then once a month thereafter. KISAQALI at a Glance Drug Name: KISQALI (ribociclib) Molecule type: Small molecule Developer: Novartis Primary Indication: HR+/HER2− breast cancer Mechanism of action: Cyclin-dependent kinases 4 and 6 inhibitor Route of administration: Oral CDK4/6 inhibitors are a type of targeted cancer therapy that work by blocking the function of cyclin-dependent kinases 4 and 6—enzymes crucial for regulating the cell cycle, particularly the progression from the G1 to S phase, where cells begin DNA replication. By inhibiting these kinases, the drugs effectively stop cancer cell proliferation, leading to growth arrest and potentially cell death. This precise mechanism makes them especially effective in treating hormone receptor-positive, HER2-negative breast cancers, among other types. The introduction and approval of CDK4/6 inhibitors have significantly reshaped the treatment approach for HR+/HER2− metastatic breast cancer. Currently, three main selective CDK4/6 inhibitors, IBRANCE (palbociclib), KISQALI (ribociclib), and VERZENIO (abemaciclib), are commonly used in combination with endocrine therapy as the first-line treatment. Notably, the NCCN now recommends KISQALI as the preferred first-line option for metastatic cases. Once endocrine and targeted therapies no longer work, chemotherapy and antibody-drug conjugates (ADCs) are typically used. IBRANCE remains the market leader among CDK4/6 inhibitors, with around 70% of U.S. patients receiving it when prescribed a drug in this class. Looking ahead, there is strong potential to extend the use of CDK4/6 inhibitors beyond HR+/HER2− advanced breast cancer. According to DelveInsight, market growth in the 7MM is expected to be fueled by rising cancer incidence, greater awareness and access to treatment, and an active pipeline of new indications. Emerging Competitors of KISQALI Some of the CDK4/6 inhibitors in the pipeline include Lerociclib (G1 Therapeutics and Pepper Bio), Atirmociclib (Pfizer), PRT3645 (Prelude Therapeutics), Trilaciclib (G1 Therapeutics), SPH4336 (Shanghai Pharma Biotherapeutics), Dalpiciclib (Jiangsu Hengrui Pharmaceuticals), BGB-43395 (BeiGene), BTX-9341 (Biotheryx), and Euthare-155008 (Shengke Pharmaceuticals), among others. In May 2024, G1 Therapeutics and Pepper Bio announced a global licensing agreement (excluding Asia-Pacific) for lerociclib, a selective CDK4/6 inhibitor. Using their COMPASS platform, Pepper Bio identified CDK4/6 as key targets for Hepatocellular carcinoma, with preclinical models showing superior efficacy. Lerociclib is now advancing to Phase II trials. Key Milestones of KISQALI In December 2024, Novartis shared updated findings from the pivotal Phase III NATALEE trial of KISQALI, highlighting its prolonged effectiveness even after treatment ends when used alongside endocrine therapy (ET). The results demonstrated a 28.5% sustained reduction in the risk of distant recurrence (HR=0.715; 95% CI 0.604–0.847; nominal P<0.0001) compared to ET alone in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC). In November 2024, Novartis announced that the European Commission (EC) had approved KISQALI, in combination with an aromatase inhibitor (AI), for use as adjuvant treatment in patients with HR-positive HER2-negative early breast cancer who are at high risk of recurrence. In September 2024, Novartis announced that the FDA has approved KISQALI, in combination with an aromatase inhibitor (AI), for adjuvant treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) who are at high risk of recurrence — including individuals with node-negative (N0) disease. In September 2020, Novartis proudly shared that KISQALI received the highest possible score—five out of five—on the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale (ESMO-MCBS) for use as a first-line treatment in premenopausal patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. In July 2018, Novartis received a new approval from the FDA for KISQALI (ribociclib) to treat women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced or metastatic breast cancer. In March 2017, the FDA approved KISQALI, in combination with an aromatase inhibitor, as a first-line endocrine-based treatment for postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2−) advanced or metastatic breast cancer. Discover how KISQALI CDK4/6 inhibitor is shaping the breast cancer treatment landscape @ KISQALI Cost KISQALI Market Dynamics KISQALI (ribociclib) is a CDK4/6 inhibitor used primarily in the treatment of HR-positive, HER2-negative breast cancer. Since its approval in 2017 by the FDA, it has become a key player in the competitive oncology market. The drug works by inhibiting cyclin-dependent kinases 4 and 6, which are responsible for the progression of many cancers, including breast cancer. KISQALI is typically used in combination with aromatase inhibitors or letrozole, offering a therapeutic advantage by enhancing anti-tumor efficacy while also maintaining manageable safety profiles. The market dynamics for KISQALI are heavily influenced by the broader competitive landscape of CDK4/6 inhibitors, with notable competitors including IBRANCE (palbociclib) and VERZENIO (abemaciclib). These drugs are all vying for market share in a segment that is expected to grow significantly due to increasing breast cancer diagnoses and the demand for targeted therapies. KISQALI has carved a niche for itself with favorable clinical trial data, including its ability to deliver improved progression-free survival rates, which is appealing to oncologists and healthcare providers. However, pricing pressures, especially in markets with significant healthcare budget constraints, and the rising popularity of combination therapies will influence KISQALI's market position in the coming years. Additionally, ongoing research and the potential for new indications could further shape KISQALI's growth trajectory. Table of Contents 1. Report Introduction 2. KISQALI: Novartis 2.1. Product Overview 2.2. Other Development Activities 2.3. Clinical Development 2.4. Clinical Trials Information 2.5. Safety and Efficacy 2.6. Product Profile 2.7. Market Assessment 2.7.1. The 7MM Analysis 2.7.1.1. Cost Assumptions and Rebate 2.7.1.2. Pricing Trends 2.7.1.3. Analogue Assessment 2.7.1.4. Launch Year and Therapy Uptake 2.7.2. The United States Market Analysis 2.7.3. EU4 and the United Kingdom Market Analysis 2.7.3.1. Germany 2.7.3.2. France 2.7.3.3. Italy 2.7.3.4. Spain 2.7.3.5. UK 2.7.4. Japan Market Analysis 2.8. Market Drivers 2.9. Market Barriers 2.10. SWOT Analysis 3. Key Cross of Marketed Competitors of KISQALI 4. Key Cross of Emerging Competitors of KISQALI Related Reports CDK4/6 Inhibitor Market CDK4/6 Inhibitor Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CDK4/6 inhibitor companies, including Pfizer, Prelude Therapeutics, G1 Therapeutics, Pepper Bio, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Sandeep Joshi Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
